Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).

Manabu Futamura Takahiro NakayamaTetsuhiro YoshinamiChiya OshiroMikiya Ishihara Midori MoritaAkira WatanabeAzusa TanigichiMasami TsukabeMasafumi ShimodaKanae NittaYoko ChiharaHiroyuki YasojimaYoshimi OuchiYoshihisa Tokumaru Norikazu Masuda

Published in: Breast cancer (Tokyo, Japan) (2023)

The efficacy and prognosis of CDK4/6i significantly differed between the NOLUS-positive and NOLUS-negative patients. This feasible method can predict patients with HR+/HER2- mBC resistant to CDK4/6i and help select a better therapeutic approach to overcome resistance.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
cell cycle
metastatic breast cancer
prognostic factors
peritoneal dialysis
patient reported outcomes
loop mediated isothermal amplification